Development Of Long-Acting Interferon As New Therapy For Pv And Et

Development of long-acting interferon as new therapy for PV and ET

Update on Long-acting Interferons for MPN

Long-acting interferon: What is the difference?

Update on Long-acting Interferons for MPN

Indication for cytoreductive therapy in ET and PV: Do we have it right?

Current therapy options and clinical outcomes analysis in patients with PV

5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera

VJHemOnc – Video Journal of Hematology & HemOnc

Management of PV, the role of interferon

The role of interferon in PV

VJHemOnc – Video Journal of Hematology & HemOnc

Management of PV, The Role of Interferon

Interferons and Myeloproliferative Neoplasms (MPNs)

Rare Disease Report

Risk-adapted treatment of ET & PV

VJHemOnc – Video Journal of Hematology & HemOnc

Novel approaches for MPNs

VJHemOnc – Video Journal of Hematology & HemOnc

Comparing Hydroxyurea and Pegylated Interferon-Alpha-2a in PV and ET

Targeted Oncology

Dr Raajit Rampal-Interferon and New MPN Therapies

MPN Advocacy & Education International

What can be learnt about using interferon in patients with myelofibrosis?

VJHemOnc – Video Journal of Hematology & HemOnc

Conversation with an MPN Specialist: Summer Updates

MPN Advocacy & Education International

The use of interferons in the treatment of MPNs

VJHemOnc – Video Journal of Hematology & HemOnc

Pegylated interferon for the treatment of polycythemia vera and essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF

VJHemOnc – Video Journal of Hematology & HemOnc